Working... Menu

Subdissociative Dose Ketamine for Treatment of Acute Pain in Subjects With Chronic Pain

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02920528
Recruitment Status : Active, not recruiting
First Posted : September 30, 2016
Last Update Posted : July 6, 2018
Air Force Research Laboratory
Information provided by (Responsible Party):
David Tanen, Los Angeles Biomedical Research Institute

Brief Summary:
This is a prospective, randomized controlled trial which will be conducted to determine whether sub-dissociative dose ketamine (SDDK) can improve pain control in subjects with chronic pain syndrome presenting to the emergency department with exacerbation of their chronic pain. The investigators also aim to determine whether use of SDDK can reduce the amount of subsequent opioid pain medications required for adequate pain relief in this population.

Condition or disease Intervention/treatment Phase
Chronic Pain Drug: Ketamine Drug: Placebo Phase 3

Detailed Description:
  1. The informed consent process will be initiated by investigators in the emergency department.
  2. All potential subjects will be informed that participation in the study could lead to a positive urine drug test that could remain positive for up to a month after the conclusion of the study.
  3. Female subjects of child bearing age, will have a pregnancy test performed prior to enrollment; any subjects who are pregnant will be excluded from this project.
  4. Each subject will be asked to grade his/her pain severity on a 100mm non-hatched visual analog scale (VAS) ranging from 0 (no pain) to 100 (worst, maximum pain).
  5. Each subject will be asked to fill out a baseline pain questionnaire
  6. Each subject will be placed on monitors for continuous pulse oximetry, Heart Rate, Respiratory Rate, and blood pressure every 5 minutes for the duration of the study of one hour and longer for any patient who needs continued care. The patients temperature will be taken prior to the start of the protocol.
  7. Each subject will have an intravenous catheter placed.
  8. Each subject will be sequentially assigned to one of three treatment groups, based on a computer-generated randomization schedule, to receive an intravenous infusion of sub-dissociative Ketamine (0.25mg/kg), sub-dissociative dose Ketamine (0.5mg/kg), or an equal amount of normal saline.
  9. All medications will be prepared by an emergency department pharmacist and all study medication intravenous bags will be identical in appearance and will be administered by the emergency department nurse caring for the patient who will be blinded to the study drug.
  10. Each subject will receive lightly tinted sunglasses to wear during the duration of the study to minimize bias as ketamine can evoke a tell-tale short- lived nystagmus
  11. Each subject will receive the study medication over a 20 minute period via an automated pump. At this point, the subjects will be asked to rate their pain on a VAS and asked if they need additional pain medication that will consist of intravenous hydromorphone with the dose and frequency determined by the discretion of the treating physician and documented on the data collection sheet.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 106 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Subdissociative Dose Ketamine for Treatment of Acute Pain in Subjects With Chronic Pain: A Randomized Controlled Trial
Actual Study Start Date : May 1, 2017
Actual Primary Completion Date : June 22, 2018
Estimated Study Completion Date : October 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Chronic Pain
Drug Information available for: Ketamine

Arm Intervention/treatment
Placebo Comparator: Placebo
placebo controlled arm
Drug: Placebo
Normal Saline
Other Name: Normal Saline

Experimental: very low dose ketamine
0.25 mg/kg of sub-dissociative ketamine as an experimental arm
Drug: Ketamine
sub-dissociative ketamine
Other Name: ketalar

Experimental: low dose ketamine
0.50 mg/kg of sub-dissociative ketamine as an experimental arm
Drug: Ketamine
sub-dissociative ketamine
Other Name: ketalar

Primary Outcome Measures :
  1. Compare pain relief between the 3 treatment groups as measured by the VAS. A decrease of at least 20mm on the VAS will be considered "significant" pain relief [ Time Frame: 1 hour ]
    Subjects pain will be assessed by VAS at 20, 40 and 60 minutes. Differences at 60 minutes will be compared for the primary outcome

Secondary Outcome Measures :
  1. Compare total dosage of IV hydromorphone needed as rescue therapy to achieved adequate pain relief [ Time Frame: 1 hour ]
    Compare need for rescue therapy at the completion of the 1 hour study

  2. Assess the risk for complications of sub-dissociative dose ketamine [ Time Frame: 1 hour ]
    Subjects will be continuously assessed for complications secondary to the sub-dissociative ketamine

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • All adult subjects over the age of 18 with chronic pain* presenting to the emergency department with exacerbation of their chronic pain as their primary complaint
  • Subjects who are willing and able to provide informed consent. *Chronic pain defined as greater > 3 months of symptoms and an initial VAS pain score > 70

Exclusion Criteria:

  • History of overt psychosis, severe hypertension as defined by Systolic Blood Pressure > 180 mm Hg or Diastolic Blood Pressure >110 mm Hg, unstable angina, Coronary Artery Disease, Congestive Heart Failure, porphyrias, thyroid disease, seizure disorder, inability to provide informed consent: dementia, non-English/Spanish speakers, subjects in custody, suicidal, or clinically intoxicated.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02920528

Layout table for location information
United States, California
Emergency Department, Harbor-UCLA Medical Center
Torrance, California, United States, 90501
Sponsors and Collaborators
Los Angeles Biomedical Research Institute
Air Force Research Laboratory
Layout table for investigator information
Principal Investigator: David Tanen, MD Los Angeles Biomedical Institute

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: David Tanen, Professor of Emergency Medicine, Los Angeles Biomedical Research Institute Identifier: NCT02920528     History of Changes
Other Study ID Numbers: 30612-01
First Posted: September 30, 2016    Key Record Dates
Last Update Posted: July 6, 2018
Last Verified: July 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Chronic Pain
Acute Pain
Neurologic Manifestations
Signs and Symptoms
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anesthetics, Dissociative
Anesthetics, Intravenous
Anesthetics, General
Central Nervous System Depressants
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action